Corporate Strategy
Who we are
In a moment of extraordinary volatility in government policy, independent analysis to sort through noise is critical. C-suite leaders, corporate development, government relations (GR), and strategy teams need forward-looking analysis to determine where policy is heading and how a company should respond. Not more information from a single source, but better, more comprehensive analysis and advice that can be used directly for financial modeling and risk analysis.
That is what we do. We do not lobby or practice law. Rather, we help companies understand and forecast market and policy changes that could create business opportunities or risks. Our differentiators are our network, our unparalleled policy and sector expertise, and our track record of forecasting what policy means for business plans and operations. We live in the weeds, uncovering the risks and opportunities of next year, not just reacting to the news of the day.
Our services
- Bespoke policy research and analysis
- Horizon Scanning & Scenario Planning
- M&A due diligence
- Commissioned reports
Our clients
- CEOs and C-suite executives
- Corporate strategy leads
- Corporate development leads
- Enterprise risk executives
- Government relations professionals
Case Studies
Capstone has a proven track record of providing in-depth analysis across a wide range of policy and regulatory issues. Our case studies demonstrate our ability to help clients navigate complex policy challenges and develop targeted revenue-driving strategies.
Contact Us
Our Latest Insights
Youth Sports, Private Equity, State Scrutiny, and the Shifting Policy Backdrop at Play
Few issues garner genuine bipartisan agreement amid widening political divisions in Washington, but access to youth sports transcends the divide. Republicans and Democrats alike champion athletics for what they offer children: health benefits, social and emotional...
Untangling the Outlook for NIH Funding and Its Impact on Pharma
Capstone believes funding for the National Institutes of Health (NIH) will remain stable for the next 3-5 years, and investors should look past headline appropriations to specific therapeutic area (TA) to assess regulatory risk. Congress continues to insulate funding...
The IRS Ruling Targeting Tax-Aware ETF Strategies
We believe the Internal Revenue Service’s (IRS) September 28th ruling taxing certain Section 351 transactions signals further restrictions on other aggressive tax-aware strategies over the next two years, which is a negative for exchange-traded fund (ETF) sponsors and...


























